Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients
- 1 November 2001
- journal article
- clinical trial
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 38 (5) , 1074-1081
- https://doi.org/10.1053/ajkd.2001.28607
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Hepatitis in patients with end‐stage renal diseaseJournal of Gastroenterology and Hepatology, 1997
- Current therapeutic trends in therapy for chronic viral hepatitisJournal of Gastroenterology and Hepatology, 1997
- THE LONG-TERM VIROLOGIC AND PATHOLOGIC IMPACT OF RENAL TRANSPLANTATION ON CHRONIC HEPATITIS B VIRUS INFECTIONTransplantation, 1996
- Ganciclovir treatment of hepatitis B virus infection in liver transplant recipientsHepatology, 1996
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B InfectionNew England Journal of Medicine, 1995
- Renal Transplantation in Asymptomatic Carriers of Hepatitis B Surface AntigenNephron, 1995
- Prevalence and Clinical Course of Hepatitis B and Hepatitis C Liver Disease in Ciclosporin-Treated Renal Allograft RecipientsNephron, 1995
- New Developments in Antiviral Therapy for Chronic Hepatitis B InfectionScandinavian Journal of Gastroenterology, 1995
- LONG-TERM RESULTS AND COMPLICATIONS IN RENAL TRANSPLANT RECIPIENTSTransplantation, 1988
- Controlled Clinical Trial of Prophylactic Human-Leukocyte Interferon in Renal TransplantationNew England Journal of Medicine, 1979